Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Katja Gessner
Institutions:
Friedrich-Alexander-Universität Erlangen-Nürnberg,
Universitätsklinikum Erlangen,
Comprehensive Cancer Center Erlangen
Observed institutions:
Friedrich-Alexander-Universität Erlangen-Nürnberg,
Universitätsklinikum Erlangen,
Comprehensive Cancer Center Erlangen
ORCID:
0000-0002-5250-9568
Observed ORCID:
0000-0002-5250-9568
OpenAlex ID:
A5099044993
A Hybrid Type III Effectiveness-Implementation Trial to Optimize Medication Safety With Oral Antitumor Therapy in Real-World: The AMBORA Competence and Consultation Center
2024
·
Lisa Cuba
, Pauline Dürr
, et al.
·
JCO Oncology Practice
·
10
Extent and Incidence of Pseudo‐Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the AMBORA Cohort: An Analysis of Real‐World Data
2025
·
Michael I. Sponfeldner
, Pauline Dürr
, et al.
·
Clinical Pharmacology & Therapeutics
·
4
PDF
Medication safety with oral antitumour therapeutics in paediatrics (youngAMBORA): A mixed-methods approach towards a tailored care program
2024
·
Phyllis Lensker
, Lisa Cuba
, et al.
·
PLoS ONE
·
4
Letters to the Editor
2025
·
Martin F. Fromm
, Michael I. Sponfeldner
, et al.
·
Deutsches Ärzteblatt international
·
2
PDF
Auswirkungen auf die Arzneimitteltherapiesicherheit und Adhärenz in der Dermato‐Onkologie: Das AMBORA‐Therapiebegleitungskonzept für orale Antitumortherapeutika
2025
·
Lisa Cuba
, Frank Dörje
, et al.
·
JDDG Journal der Deutschen Dermatologischen Gesellschaft
PDF
Implications for medication safety and adherence in dermato‐oncology: The AMBORA care program for oral antitumor therapeutics
2025
·
Lisa Cuba
, Frank Dörje
, et al.
·
JDDG Journal der Deutschen Dermatologischen Gesellschaft
PDF
Show more works
View as search
Works count:
6
Citation count:
20
H-index:
3
I10-index:
1
Year
Topic
Type